GET DAILY SIGNALSBaird Medical (BDMD) Drops -81.6% in 30 Days Amid Dilution and Rating Concerns
Key Takeaways
- Baird Medical (BDMD) shares fell roughly 81.6% over the trailing 30 days, from about $0.75 to $0.14, extending a broader multi-month downtrend.
- The decline was driven by dilution risk from a $50 million shelf registration and a priced offering, a Weiss Ratings downgrade to "Sell," and heavy sell-side volume in a thinly traded micro-cap.
- Shares have traded well below $1.00, a level that raises Nasdaq minimum bid price listing compliance considerations for the company.
- H1 2026 results showed revenue up 24.6% to about $9.9 million and a return to marginal profitability, but full-year 2025 revenue fell 39.2%.
- Liquidity remains a core risk, with cash and restricted cash of approximately $0.23 million reported as of June 30, 2026.
- For deeper analysis of this stock, explore its Price Targets, Earnings, and Forecast pages.
- Explore Trending AI Robots to see how algorithmic trading tools are currently positioning across the market.
Baird Medical (BDMD) Company Overview and Market Position
Baird Medical Investment Holdings Ltd. is a Guangzhou, China-based medical device company founded in 2012. The company designs, develops, manufactures, and sells minimally invasive microwave ablation (MWA) systems and needles used to treat benign and malignant tumors, including thyroid nodules, liver cancer, lung cancer, breast lumps, and uterine fibroids. Its lead product is a microwave ablation system that received U.S. FDA 510(k) clearance for soft tissue ablation and is being launched in the United States primarily for the treatment of benign thyroid nodules. Baird Medical was the first company to obtain a Class III medical device registration in China for MWA devices specifically indicated for thyroid nodules, and it is also developing IRE-based products and an AI-powered robotic ablation system. The company listed on Nasdaq in October 2024 through a business combination with ExcelFin Acquisition Corp., and investors follow the stock for its U.S. commercialization progress and expanding pipeline.
Baird Medical (BDMD) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, BDMD declined from a close of about $0.75 to roughly $0.14, a drop of approximately 81.6%. The decline was not linear: the stock traded near $0.75 in early October before sharp, high-volume selloffs in late October accelerated the move toward $0.14.
The quarterly picture is similarly negative. From about $1.22 in early August, shares fell to roughly $0.14 by early November, a decline of nearly 89%. This reflects a sustained downward trend rather than a single isolated event, with selling pressure intensifying after a registered offering and a ratings downgrade. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
What Drove BDMD Stock Price in the Last 30 Days
Several verified factors contributed to the sharp decline. On September 24, 2026, the company priced an offering under its shelf registration, raising dilution concerns in an already thinly traded security. The company had earlier filed a $50 million shelf registration statement on August 6, 2026. On October 6, 2026, Weiss Ratings issued a downgrade on Baird Medical with a "Sell" rating, adding to negative sentiment.
The selloff pushed the stock below $1.00, a threshold that raises Nasdaq minimum bid price listing compliance considerations. Trading volume expanded dramatically in late October and early November, reflecting heavy selling pressure in a low-priced, low-float micro-cap. Broader weakness among Chinese concept stocks during October also weighed on the shares, compounding company-specific concerns around liquidity and the pace at which regulatory approvals are converting into commercial sales.
What Drove BDMD Stock Performance Over the Last Quarter
The multi-month downtrend reflects a broader narrative around a China-based micro-cap navigating a transition toward U.S. commercialization. In August 2026, the company's shelf registration and prospectus updates highlighted a resale overhang and ongoing China-related and Holding Foreign Companies Accountable Act (HFCAA) risks. In September, preliminary H1 2026 results showed revenue up 24.6% year over year and a swing to a narrow net profit, but the figures were preliminary and unaudited, and full-year 2025 revenue had fallen 39.2% due to a policy-related slowdown in mainland China. The combination of modest profitability, a low cash balance, dilution risk, and a sub-$1.00 share price kept sentiment under pressure throughout the quarter.
BDMD Stock Forecast Drivers: What Investors Should Watch Next
Going forward, investors are likely to focus on whether Baird Medical's FDA-cleared microwave ablation system converts into sustained U.S. sales, and whether international regulatory approvals in markets such as Vietnam and Egypt translate into reported revenue. Audited interim financial results, any further capital-raising activity under the shelf registration, and the company's cash position will also be closely monitored. Listing compliance remains a key watch item while shares trade below $1.00, as does any update on auditor-related HFCAA risks. Developments in mainland China healthcare policy, which contributed to the 2025 revenue decline, and the broader sentiment toward Chinese concept stocks may continue to influence price action. These are informational considerations only and not investment recommendations.
Exploring AI Tools for Stock Analysis
In my own research process, I have found Tickeron’s Trending AI Robots to be a practical way to review how algorithmic strategies are currently positioned across various tickers. The section highlights top-performing bots from a range of AI-driven approaches, allowing users to compare options based on timeframe and risk profile without sifting through every available strategy. This complements traditional analysis when evaluating names like BDMD that face multiple moving parts.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Experienced trader focused on market analysis, identifying trading opportunities, and developing custom trading signals based on market trends, price action, and data-driven insights. Join my Trader Club to follow my latest analysis, trading ideas, and active signals: https://tickeron.com/app/trader-club/103/view?tab=active§ion=trades&via=john
BDMD's Indicator enters downward trend
The Aroon Indicator for BDMD entered a downward trend on November 03, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 168 similar instances where the Aroon Indicator formed such a pattern. In 152 of the 168 cases the stock moved lower. This puts the odds of a downward move at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 12, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on BDMD as a result. In 34 of 72 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 47%.
The Moving Average Convergence Divergence Histogram (MACD) for BDMD turned negative on October 14, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In 14 of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at 31%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BDMD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 83%.
Bullish Trend Analysis
The RSI Indicator shows that the ticker has stayed in the oversold zone for 15 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 14 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +8.36% 3-day Advance, the price is estimated to grow further. Considering data from situations where BDMD advanced for three days, in 68 of 116 cases, the price rose further within the following month. The odds of a continued upward trend are 59%.
BDMD may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 35 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.108) is normal, around the industry mean (4.170). P/E Ratio (-0.212) is within average values for comparable stocks, (1.500). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.010) among similar stocks. P/S Ratio (1.371) is also within normal values, averaging (40.124).
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 98 (best 1 - 100 worst), indicating slightly worse than average price growth. BDMD’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BDMD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry MedicalNursingServices
Advertisement